| 8.5389 -0.211 (-2.41%) | 04-20 11:15 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 10.31 | 1-year : | 12.04 |
| Resists | First : | 8.82 | Second : | 10.31 |
| Pivot price | 8.3  |
|||
| Supports | First : | 7.94 | Second : | 7.38 |
| MAs | MA(5) : | 8.62 |
MA(20) : | 8.13 |
| MA(100) : | 8.78 |
MA(250) : | 8.98 |
|
| MACD | MACD : | 0 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 87.2 |
D(3) : | 89.8 |
| RSI | RSI(14): 55.9 |
|||
| 52-week | High : | 10.95 | Low : | 6.78 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ GRFS ] has closed below upper band by 27.0%. Bollinger Bands are 30% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 8.84 - 8.88 | 8.88 - 8.91 |
| Low: | 8.48 - 8.53 | 8.53 - 8.56 |
| Close: | 8.68 - 8.75 | 8.75 - 8.81 |
Grifols, S.A. engages in the procurement, manufacture, preparation, and sale of therapeutic products, primarily hemoderivatives. The company operates through Bioscience, Hospital, Diagnostic, Bio Supplies, and Others divisions. The Bioscience division researches, develops, produces, and markets plasma-derived medicines and other innovative solutions to treat patients with chronic, rare, prevalent, and life-threatening diseases. It offers immunoglobulins, alpha-1 antitrypsin, albumin, clotting factors, and hyperimmune globulins. The Hospital division offers non-biological pharmaceutical products and medical supplies clinical nutrition, intravenous therapy, and medical devices. The Diagnostic division researches, develops, produces, and commercializes diagnostic products that span the healthcare continuumfrom prevention, screening, diagnosis, and prognosis to disease and treatment monitoringto serve professionals. The Bio Supplies division provides biological materials for life-science research, clinical trials, and for manufacturing pharmaceutical and diagnostic products. Its products and services are used by healthcare providers to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases, and other medical conditions. The company serves public and private customers; and wholesalers, distributors, group purchasing organizations, blood banks, hospitals and care institutions, and national health systems. Grifols, S.A. has a technology collaboration agreement with Mondragon. The company was founded in 1940 and is headquartered in Barcelona, Spain.
Fri, 17 Apr 2026
Grifols (NASDAQ: GRFS) 2025 revenue rises as leverage and risk factors stay elevated - Stock Titan
Fri, 17 Apr 2026
Health Canada Imposes New Conditions on Grifols, S.A. (GRFS) Plasma Collection Centers - Insider Monkey
Wed, 15 Apr 2026
Grifols, S.A. (NASDAQ:GRFS) Short Interest Update - MarketBeat
Wed, 15 Apr 2026
Grifols Refinances 2027 Debt and Extends Maturities with Multi-Billion Term Loan B Package - The Globe and Mail
Wed, 15 Apr 2026
Grifols considers IPO of part of its US biopharma business - MSN
Tue, 14 Apr 2026
[6-K] Grifols SA Current Report (Foreign Issuer) | GRFS SEC Filing - Form 6-K - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - General
|
|
| Shares Out | 258 (M) |
| Shares Float | 417 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 57.4 (%) |
| Shares Short | 7,020 (K) |
| Shares Short P.Month | 7,110 (K) |
| EPS | 0.64 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 4.57 |
| Profit Margin | 5.3 % |
| Operating Margin | 17.5 % |
| Return on Assets (ttm) | 4.2 % |
| Return on Equity (ttm) | 6.1 % |
| Qtrly Rev. Growth | 0.3 % |
| Gross Profit (p.s.) | 11.3 |
| Sales Per Share | 29.12 |
| EBITDA (p.s.) | 6.58 |
| Qtrly Earnings Growth | 43.5 % |
| Operating Cash Flow | 1,050 (M) |
| Levered Free Cash Flow | 1,030 (M) |
| PE Ratio | 13.19 |
| PEG Ratio | 0.1 |
| Price to Book value | 1.87 |
| Price to Sales | 0.29 |
| Price to Cash Flow | 2.1 |
| Dividend | 0.17 |
| Forward Dividend | 0 |
| Dividend Yield | 1.9% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|